Herpes Simplex Virus Vector–Mediated Expression of Interleukin-10 Reduces Below-Level Central Neuropathic Pain After Spinal Cord Injury

Background. Neuroimmune activation in the spinal dorsal horn plays an important role in the pathogenesis of chronic pain after peripheral nerve injury. Objective. The aim of this study was to examine the role of neuroimmune activation in below-level neuropathic pain after traumatic spinal cord injury (SCI). Methods. Right hemilateral SCI was created in male Sprague–Dawley rats by controlled blunt impact through a T12 laminectomy. Pain-related behaviors were assessed using both evoked reflex responses and an operant conflict-avoidance test. Neuroimmune activation was blocked by the anti-inflammatory cytokine interleukin-10 (IL-10) delivered by a nonreplicating herpes simplex virus (HSV)–based gene transfer vector (vIL10). Markers of neuroimmune activation were assessed using immunohistochemistry and Western blot. Results. One week after SCI, injured animals demonstrated mechanical allodynia, thermal hyperalgesia, and mechanical hyperalgesia in the hind limbs below the level of injury. Animals inoculated with vIL10 had a statistically significant reduction in all of these measures compared to injured rats or injured rats inoculated with control vector. Conflict-avoidance behavior of injured rats inoculated with vIL10 was consistent with significantly reduced pain compared with injured rats injected with control vector. These behavioral results correlated with a significant decrease in spinal tumor necrosis factor α (mTNFα) expression assessed by Western blot and astrocyte activation assessed by glial fibrillary acidic protein immunohistochemistry. Conclusion. Below-level pain after SCI is characterized by neuroimmune activation (increase mTNFα and astrocyte activation). Blunting of the neuroimmune response by HSV-mediated delivery of IL-10 reduced pain-related behaviors, and may represent a potential novel therapeutic agent.

[1]  James Goss,et al.  Gene therapy for pain: Results of a phase I clinical trial , 2011, Annals of neurology.

[2]  L. Audoly,et al.  A novel role of prostaglandin E2 in neuropathic pain , 2011, Glia.

[3]  C. Vierck,et al.  Reflex and pain behaviors are not equivalent: Lessons from spinal cord injury , 2010, PAIN®.

[4]  J. Nyengaard,et al.  Spinal-, brainstem- and cerebrally mediated responses at- and below-level of a spinal cord contusion in rats: Evaluation of pain-like behavior , 2010, PAIN®.

[5]  T. Morrow,et al.  Pregabalin modulates motivational but not sensory pain behaviors in rats with peripheral nerve injury , 2010 .

[6]  R. Ji,et al.  Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. , 2010, Pharmacology & therapeutics.

[7]  Ryan Insolera,et al.  IL-10 promotes neuronal survival following spinal cord injury , 2009, Experimental Neurology.

[8]  Ryan Insolera,et al.  Interleukin‐10 provides direct trophic support to neurons , 2009, Journal of neurochemistry.

[9]  C. Hulsebosch,et al.  Remote astrocytic and microglial activation modulates neuronal hyperexcitability and below-level neuropathic pain after spinal injury in rat , 2009, Neuroscience.

[10]  C. Hulsebosch.  Gliopathy ensures persistent inflammation and chronic pain after spinal cord injury , 2008, Experimental Neurology.

[11]  C. Hulsebosch,et al.  Propentofylline attenuates allodynia, glial activation and modulates GABAergic tone after spinal cord injury in the rat , 2008, PAIN.

[12]  D. Fink,et al.  HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor α in spinal cord microglia , 2008, Gene Therapy.

[13]  R. Ji,et al.  Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine , 2007, Brain, Behavior, and Immunity.

[14]  C. Hulsebosch,et al.  Increases in the activated forms of ERK 1/2, p38 MAPK, and CREB are correlated with the expression of at-level mechanical allodynia following spinal cord injury , 2006, Experimental Neurology.

[15]  J. Glorioso,et al.  Tumor necrosis factor–α contributes to below‐level neuropathic pain after spinal cord injury , 2006 .

[16]  S. Waxman,et al.  Activated Microglia Contribute to the Maintenance of Chronic Pain after Spinal Cord Injury , 2006, The Journal of Neuroscience.

[17]  S. Maier,et al.  Glia: novel counter-regulators of opioid analgesia , 2005, Trends in Neurosciences.

[18]  R. Yezierski,et al.  Activation of the ERK1/2 signaling cascade by excitotoxic spinal cord injury. , 2005, Brain research. Molecular brain research.

[19]  J. Glorioso,et al.  Long-term neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  S. Maier,et al.  Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation , 2005, Pain.

[21]  J. Glorioso,et al.  Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. , 2004, Annual review of microbiology.

[22]  J. Glorioso,et al.  Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  S. Maier,et al.  Glial activation and pathological pain , 2004, Neurochemistry International.

[24]  R. Myers,et al.  TNF-&agr; and TNF-&agr; Receptor Type 1 Upregulation in Glia and Neurons After Peripheral Nerve Injury: Studies in Murine DRG and Spinal Cord , 2004 .

[25]  P. Blumbergs,et al.  Early Expression and Cellular Localization of Proinflammatory Cytokines Interleukin-1β, Interleukin-6, and Tumor Necrosis Factor-&agr; in Human Traumatic Spinal Cord Injury , 2004, Spine.

[26]  N. Finnerup,et al.  Spinal cord injury pain – mechanisms and treatment , 2004, European journal of neurology.

[27]  B. Dobkin,et al.  Basic advances and new avenues in therapy of spinal cord injury. , 2004, Annual review of medicine.

[28]  S. Koizumi,et al.  P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury , 2003, Nature.

[29]  J. Deleo,et al.  Inhibition of Microglial Activation Attenuates the Development but Not Existing Hypersensitivity in a Rat Model of Neuropathy , 2003, Journal of Pharmacology and Experimental Therapeutics.

[30]  L. Sorkin,et al.  Tumor Necrosis Factor-α Induces Mechanical Allodynia after Spinal Nerve Ligation by Activation of p38 MAPK in Primary Sensory Neurons , 2003, The Journal of Neuroscience.

[31]  H. Rhim,et al.  Increased Production of Tumor Necrosis Factor-α Induces Apoptosis after Traumatic Spinal Cord Injury in Rats , 2003 .

[32]  Alexander Sasha Rabchevsky,et al.  Experimental modeling of spinal cord injury: characterization of a force-defined injury device. , 2003, Journal of neurotrauma.

[33]  J. Leysen,et al.  Expression and regulation of interleukin‐10 and interleukin‐10 receptor in rat astroglial and microglial cells , 2002, The European journal of neuroscience.

[34]  B. Winkelstein,et al.  Lumbar Nerve Root Injury Induces Central Nervous System Neuroimmune Activation and Neuroinflammation in the Rat: Relationship to Painful Radiculopathy , 2002, Spine.

[35]  J. Mcdonald,et al.  Spinal-cord injury , 2002, The Lancet.

[36]  E. Boddeke,et al.  Involvement of chemokines in pain. , 2001, European journal of pharmacology.

[37]  S. Maier,et al.  Intrathecal HIV-1 Envelope Glycoprotein gp120 Induces Enhanced Pain States Mediated by Spinal Cord Proinflammatory Cytokines , 2001, The Journal of Neuroscience.

[38]  J. Deleo,et al.  Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain , 2001, Neuroscience.

[39]  R. Yezierski,et al.  Effects of Interleukin-10 (IL-10) on Pain Behavior and Gene Expression Following Excitotoxic Spinal Cord Injury in the Rat , 2001, Experimental Neurology.

[40]  C. Vierck,et al.  Pain following spinal cord injury: animal models and mechanistic studies , 2000, Pain.

[41]  J. Weinstein,et al.  Spinal glial activation and cytokine expression after lumbar root injury in the rat. , 2000, Spine.

[42]  R. Yezierski,et al.  Neuroprotective Effects of Interleukin-10 Following Excitotoxic Spinal Cord Injury , 1999, Experimental Neurology.

[43]  M. C. Acosta,et al.  Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats. , 1999, Journal of neurotrauma.

[44]  C. Hulsebosch,et al.  Spinal Cord Injury and Anti-NGF Treatment Results in Changes in CGRP Density and Distribution in the Dorsal Horn in the Rat , 1997, Experimental Neurology.

[45]  C. Hulsebosch,et al.  Chronic central pain after spinal cord injury. , 1997, Journal of neurotrauma.

[46]  B. Stokes,et al.  Cellular inflammatory response after spinal cord injury in sprague‐dawley and lewis rats , 1997, The Journal of comparative neurology.

[47]  A. Malhotra,et al.  Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[48]  R. Adkins,et al.  Pain and depression in acute traumatic spinal cord injury: origins of chronic problematic pain? , 1996, Archives of physical medicine and rehabilitation.

[49]  D. Basso,et al.  A sensitive and reliable locomotor rating scale for open field testing in rats. , 1995, Journal of neurotrauma.

[50]  T. Yaksh,et al.  Quantitative assessment of tactile allodynia in the rat paw , 1994, Journal of Neuroscience Methods.

[51]  L. Mucke,et al.  Rapid activation of astrocyte-specific expression of GFAP-lacZ transgene by focal injury. , 1991, The New biologist.

[52]  R. Dubner,et al.  A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia , 1987, Pain.

[53]  R. Lo,et al.  A method for measurement of analgesic activity on inflamed tissue. , 1957 .

[54]  J. Glorioso,et al.  Herpes vector-mediated gene transfer in the treatment of chronic pain. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  J. Glorioso,et al.  Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. , 2006, Annals of neurology.

[56]  C. Vierck.  Animal models of pain , 2006 .

[57]  R. Myers,et al.  TNF-alpha and TNF-alpha receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies in murine DRG and spinal cord. , 2004, Spine.

[58]  J. Glorioso,et al.  Gene therapy: Novel treatments for polyneuropathy and chronic pain , 2004, Current neurology and neuroscience reports.

[59]  L. Sorkin,et al.  Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[60]  W. Dixon,et al.  Efficient analysis of experimental observations. , 1980, Annual review of pharmacology and toxicology.

[61]  L. O. Randall,et al.  A method for measurement of analgesic activity on inflamed tissue. , 1957, Archives internationales de pharmacodynamie et de therapie.